← Back to Search

AKT Kinase Inhibitor

Capivasertib for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to disease progression or discontinuation from the study (up to 15 months)
Awards & highlights

Summary

This trial tests how capivasertib affects the processing of midazolam in patients with ER-positive breast cancer. Capivasertib aims to stop cancer cell growth by interfering with specific proteins. Midazolam helps measure this effect. Capivasertib is a potent drug showing promise in various breast cancer trials.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to disease progression or discontinuation from the study (up to 15 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to disease progression or discontinuation from the study (up to 15 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Midazolam AUCinf
Midazolam Cmax
Secondary outcome measures
Capivasertib AUCτ
Capivasertib CL/F
Capivasertib Cmax
+12 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (Midazolam + Capivasertib)Experimental Treatment2 Interventions
Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capivasertib
2021
Completed Phase 1
~130
Midazolam
2018
Completed Phase 4
~1910

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,302 Previous Clinical Trials
288,624,578 Total Patients Enrolled
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top